Blog

For millions of older adults worldwide, the diagnosis of neovascular age-related macular degeneration (nAMD) has historically signaled the frightening prospect of irreversible vision loss. This condition, characterized by the growth of abnormal, leaky blood vessels under the retina, has been managed for years with a standard of care that, while effective, comes with a significant […]

For many, the thought of eyelid surgery, or blepharoplasty, conjures images of purely cosmetic enhancement. However, a significant number of people seek this procedure for functional reasons—to improve a sagging eyelid that obstructs vision. A common concern for both patients and surgeons has been the potential for the surgery to cause or worsen dry eye

For millions of people around the world, the persistent discomfort of dry eye disease is a daily reality. Characterized by a stinging sensation, redness, blurred vision, and a feeling of grit in the eyes, this condition can significantly impact quality of life. While artificial tears and other treatments have offered some relief, the search for

The landscape of vision care is on the cusp of a monumental transformation. According to recent market analysis, the global ophthalmic therapeutics market is projected to surge, reaching a staggering valuation of $48.3 billion by the year 2034. This explosive growth underscores a critical global shift: the increasing prevalence of eye diseases and a corresponding,

For millions, the sensation of dry, gritty, itchy, or inexplicably watery eyes is a daily frustration. Traditionally, Dry Eye Disease (DED) has been simplified as a mere lack of tears. But what if the problem isn’t the *quantity* of your tears, but the *quality*? Groundbreaking research is shifting the paradigm, revealing that Dry Eye is

For millions of people living with retinal degenerative diseases, the world slowly fades to black. Conditions like age-related macular degeneration and retinitis pigmentosa rob individuals of their sight by causing the light-sensitive photoreceptor cells in the retina to die. While the rest of the eye’s circuitry may remain intact, the loss of these critical cells

In a significant move that underscores the growing importance of genetic medicine, pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire MeiraGTx’s gene therapy program for a substantial $445 million upfront, with a potential total value reaching $475 million. This strategic acquisition is poised to accelerate the development of cutting-edge treatments for inherited